Pneumococcal Disease News and Research RSS Feed - Pneumococcal Disease News and Research

Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria. [More]
Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV). [More]
Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

One of the key reasons why children are missed by immunization programs, particularly in developing countries where Médecins Sans Frontières (MSF) works, is that the products that we currently have in their present formulation are not well-suited to the places that have the most un-immunized children. These are the most challenging contexts to work in. [More]
FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine. [More]
High vaccine prices ignored by ‘Decade of Vaccines’ blueprint

High vaccine prices ignored by ‘Decade of Vaccines’ blueprint

Governments meeting at the World Health Organization’s Executive Board (WHO EB) this week must seize the opportunity to improve serious shortcomings in the document that will drive the global community’s vaccines response in the next few years. If they fail to do so, key reasons why children continue to be missed by immunisation programmes will be left unaddressed. [More]
Madagascar faces challenges in vaccinating children

Madagascar faces challenges in vaccinating children

"In Madagascar, pneumonia is responsible for 21 percent of deaths among children under five years old -- making it the leading cause of death for this age group," but "[t]he recent introduction of a vaccine to protect against pneumococcal disease, the leading cause of severe childhood pneumonia, is attempting to reduce the thousands of child deaths that occur every year in" the country, IRIN reports. [More]
Patients with COPD more likely to develop serious bacterial infections

Patients with COPD more likely to develop serious bacterial infections

It is well known that COPD patients run a higher risk of contracting respiratory infections. However, a new thesis from Lund University in Sweden shows that they are also at higher risk of other bacterial infections, such as tuberculosis (TB) and pneumococcal and staphylococcal infections that can cause serious illness. [More]
EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

Pfizer Inc. announced today that the European Commission has approved expanding the use of the company's pneumococcal conjugate vaccine, Prevenar 13(pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae. [More]
Pneumococcal disease risk increased in mental health patients

Pneumococcal disease risk increased in mental health patients

Patients with severe mental illness are at increased risk for pneumococcal disease, results from a UK study suggest. [More]

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports

IRIN examines how the WHO's recent declaration that the MenAfriVac meningitis A vaccine can be transported or stored for up to four days without refrigeration will affect immunization campaigns in Africa's meningitis belt, which runs from Senegal to Ethiopia. [More]
Promising results for pneumococcal vaccine

Promising results for pneumococcal vaccine

Research published in The Lancet shows that the PHiD-CV10 vaccine is highly effective at protecting children against invasive pneumococcal disease. [More]

New pneumococcal vaccine highly effective in infants

A new conjugate vaccine is highly effective (93–100%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most vulnerable to infection, according to new research published Online First in The Lancet. [More]
Flu virus suppresses body's ability to defend against bacteria

Flu virus suppresses body's ability to defend against bacteria

When infected with influenza, the body becomes an easy target for bacteria. The flu virus alters the host's immune system and compromises its capacity to effectively fight off bacterial infections. Now, a team of immunologists at the Helmholtz Centre for Infection Research (HZI) and cooperation partners has discovered that an immune system molecule called TLR7 is partly to blame. The molecule recognizes the viral genome - and then signals scavenger cells of the immune system to ingest fewer bacteria. [More]
NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases. [More]
Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis. [More]
Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age. [More]
Nottingham expert to study impact of gluten intolerance on patients in the UK

Nottingham expert to study impact of gluten intolerance on patients in the UK

A University of Nottingham expert has been awarded -80,000 by two national charities to study the impact of gluten intolerance on patients in the UK. [More]
Polymorphism ’protective in pneumococcal disease’

Polymorphism ’protective in pneumococcal disease’

Patients with invasive pneumococcal disease who have the FcyRIIa-R/R131 polymorphism may have better survival outcomes than those without the genotype, suggest study findings. [More]
New method can screen for bacterial genes that are expressed during meningitis

New method can screen for bacterial genes that are expressed during meningitis

Bacterial meningitis is an infection of the meninges, the protective membrane that covers the spinal cord and brain. Children, elderly patients and immunocompromised patients are at a higher risk for the development of severe bacterial meningitis. Recently, researchers at the University of Adelaide in Australia sought to identify new vaccine targets in Streptococcus pneumoniae, which is the most common cause of bacterial meningitis in the world. [More]
Efforts to stem childhood mortality in Ghana will not be enough to reach MDG, UNICEF official says

Efforts to stem childhood mortality in Ghana will not be enough to reach MDG, UNICEF official says

Anirban Chatterjee, chief of health and nutrition for UNICEF in Ghana, said the country "is doing a lot" to fight child mortality -- referring to a recently launched vaccination campaign and an initiative to educate mothers about nutrition -- but "I don't think it's enough" to reach the fourth U.N. Millennium Development Goal (MDG) to reduce the under-five mortality rate by two thirds by 2015, Inter Press Service reports. [More]